Rockville, Maryland — September 23, 2026 — The global laryngeal stents market is valued at USD 70.0 million in 2026 and is projected to reach USD 144.3 million by 2036, expanding at a 7.5% CAGR during the 2026–2036 forecast period, according to Fact.MR. Demand is supported by laryngotracheal stenosis, reconstructive airway surgery, pediatric airway reconstruction, and the need to maintain or stabilize narrowed or reconstructed airway segments. NICE identifies stent insertion among endoscopic treatment options for severe established subglottic or tracheal stenosis.

The market is also being influenced by developments in patient-specific airway treatment. A 2025 review published in Frontiers in Pediatrics notes that acquired pediatric subglottic stenosis is commonly associated with prolonged endotracheal intubation and that intralaryngeal stents may be used following selected double-stage reconstruction procedures to support healing and limit restenosis.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=7661

Global Segment Leaders

Product — Self-expandable Stents: 36.8% share in 2026. Self-expandable stents lead the product segment because they provide continuous radial support while adapting to changes in airway diameter and can be delivered endoscopically.
End Use — Hospitals: 44.1% share in 2026. Hospitals remain the principal purchasing environment because complex stenting can require anesthesia, endoscopy, airway-rescue capability, multidisciplinary care, and postoperative assessment.
Application — Child: 55.2% share in 2026. Pediatric laryngotracheal reconstruction can require temporary stenting to support grafts and maintain the reconstructed airway during healing.
Technology — Endoscopic Stent Placement Technology: 55.6% share in 2026. Direct visualization enables clinicians to identify stenotic segments, position devices, and preserve access for subsequent inspection or removal.
Country-Level Performance

Country

CAGR

Key Growth Driver

Germany

8.2%

The Robert Koch Institute recorded 3,067 new laryngeal cancer cases in 2022, supporting demand associated with complex cancer surgery and post-treatment airway management.

Brazil

7.5%

Brazil's INCA estimates 8,510 new laryngeal cancer cases annually for 2026–2028, creating potential demand for airway stabilization following tumor treatment, reconstruction, or stenosis management.

USA

6.8%

The National Cancer Institute estimates 12,290 new laryngeal cancer cases in 2026, while tertiary airway programs also manage post-intubation stenosis, trauma, and recurrent airway narrowing.

U.K.

6.1%

NICE identifies stent insertion among treatment options for severe airway narrowing, while Cancer Research UK reports around 2,300 laryngeal cancer diagnoses annually.

Japan

5.4%

Japan recorded 4,648 laryngeal cancer diagnoses in 2023, according to the National Cancer Center, supporting specialist laryngeal surgery and postoperative airway management.

Regional Context

Germany and Brazil represent the faster-growing country markets covered by Fact.MR, with projected CAGRs of 8.2% and 7.5%, respectively. Germany combines specialist ENT capabilities with a measurable head-and-neck oncology caseload, while Brazil's public oncology services face a continuing laryngeal cancer treatment burden and concentrate complex procedures in referral hospitals.

The USA and U.K. are projected to expand at 6.8% and 6.1%, respectively. U.S. demand is supported by a broad tertiary-care network and research into customized airway stents, while the U.K. has defined clinical guidance for endoscopic management of severe airway narrowing. Japan, at 5.4%, combines a continuing laryngeal cancer treatment population with advanced endoscopic practice and precision-device capabilities.

The full report covers North America, Latin America, Europe, East Asia, South Asia and Pacific, and the Middle East & Africa, with country-level analysis for Germany, Brazil, USA, U.K., and Japan.

Competitive Landscape

Key companies profiled by Fact.MR include Boston Medical Products, Inc. and Zimmer Biomet through Biomet Microfixation/Walter Lorenz Surgical. Boston Medical Products supplies the Montgomery Laryngeal Stent, Rutter Supra-Stomal Stent, and related laryngeal keels in pediatric and adult sizes. Zimmer Biomet also maintains laryngeal-stent registrations through Biomet Microfixation/Walter Lorenz Surgical.

The report's cited product and regulatory developments include Boston Medical Products' 2026 Montgomery Laryngeal Stent and Rutter Supra-Stomal Stent, as well as 2026 U.S. Food and Drug Administration Global Unique Device Identification Database records for polymeric laryngeal stents. The report also cites a 2015 Therapeutic Goods Administration record involving Zimmer Biomet Pty Ltd and a laryngeal stent.

Fact.MR's analysis identifies competition around airway-specific sizing, material behavior, removability, and procedural compatibility. Product selection also considers migration, mucosal trauma, granulation, mucus retention, and the potential need for repeat intervention.

Explore More Related Studies Published by Fact.MR Research

Omics Lab Services Market

Antimicrobial PPE Market

Color Correcting Glasses Market

Intraoral X-Ray Market

About Fact.MR

Fact.MR is a leading provider of market research and consulting services, offering syndicated and customized research across industries including healthcare, medical devices, and life sciences.

For more information on the full report, visit: Laryngeal Stents Market